Seikagaku Past Earnings Performance
Past criteria checks 5/6
Seikagaku has been growing earnings at an average annual rate of 45.2%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 5.7% per year. Seikagaku's return on equity is 2.7%, and it has net margins of 5.3%.
Key information
45.2%
Earnings growth rate
45.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 5.7% |
| Return on equity | 2.7% |
| Net Margin | 5.3% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Seikagaku makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 38,362 | 2,015 | 9,602 | 7,317 |
| 30 Jun 24 | 36,574 | 2,200 | 9,280 | 7,303 |
| 31 Mar 24 | 36,213 | 2,186 | 8,960 | 7,484 |
| 31 Dec 23 | 34,678 | 1,309 | 8,789 | 7,694 |
| 30 Sep 23 | 34,259 | 1,197 | 8,445 | 7,954 |
| 30 Jun 23 | 34,810 | 2,630 | 8,235 | 8,002 |
| 31 Mar 23 | 33,456 | 2,236 | 7,959 | 7,951 |
| 31 Dec 22 | 32,868 | 1,997 | 7,818 | 8,505 |
| 30 Sep 22 | 31,579 | 1,855 | 7,509 | 8,610 |
| 30 Jun 22 | 31,374 | 1,574 | 7,214 | 8,756 |
| 31 Mar 22 | 34,851 | 3,733 | 7,028 | 9,005 |
| 31 Dec 21 | 34,994 | 7,747 | 7,085 | 7,684 |
| 30 Sep 21 | 34,659 | 8,305 | 6,982 | 7,476 |
| 30 Jun 21 | 32,474 | 7,385 | 6,929 | 7,530 |
| 31 Mar 21 | 27,662 | 4,262 | 6,809 | 7,209 |
| 31 Dec 20 | 26,215 | 821 | 6,617 | 7,800 |
| 30 Sep 20 | 26,620 | 903 | 6,834 | 7,405 |
| 30 Jun 20 | 27,965 | -11,290 | 7,057 | 7,204 |
| 31 Mar 20 | 28,642 | -10,839 | 7,292 | 6,877 |
| 31 Dec 19 | 30,038 | -9,790 | 7,329 | 6,613 |
| 30 Sep 19 | 29,683 | -10,434 | 7,274 | 6,868 |
| 30 Jun 19 | 28,807 | 2,020 | 7,138 | 6,873 |
| 31 Mar 19 | 28,384 | 2,244 | 7,144 | 7,148 |
| 31 Dec 18 | 28,360 | 1,825 | 7,252 | 8,250 |
| 30 Sep 18 | 28,936 | 2,284 | 7,270 | 8,490 |
| 30 Jun 18 | 29,893 | 4,203 | 7,390 | 8,413 |
| 31 Mar 18 | 30,175 | 3,922 | 7,337 | 8,408 |
| 31 Dec 17 | 30,862 | 4,656 | 7,212 | 7,218 |
| 30 Sep 17 | 29,999 | 4,324 | 7,157 | 6,930 |
| 30 Jun 17 | 28,822 | 2,423 | 7,104 | 7,100 |
| 31 Mar 17 | 29,589 | 1,787 | 7,225 | 7,834 |
| 31 Dec 16 | 29,653 | 1,042 | 7,246 | 8,781 |
| 30 Sep 16 | 30,093 | 1,650 | 7,310 | 9,009 |
| 30 Jun 16 | 31,475 | 1,833 | 7,372 | 9,163 |
| 31 Mar 16 | 30,962 | 2,578 | 7,297 | 8,649 |
| 31 Dec 15 | 30,884 | 3,625 | 7,212 | 8,082 |
| 30 Sep 15 | 31,229 | 3,904 | 7,071 | 8,498 |
| 30 Jun 15 | 29,707 | 3,431 | 6,900 | 8,309 |
| 31 Mar 15 | 29,522 | 3,650 | 6,862 | 8,146 |
| 31 Dec 14 | 28,567 | 3,135 | 6,834 | 7,725 |
| 30 Sep 14 | 28,456 | 3,314 | 6,888 | 6,917 |
| 30 Jun 14 | 29,544 | 3,859 | 6,979 | 6,909 |
| 31 Mar 14 | 29,614 | 4,745 | 6,864 | 6,588 |
| 31 Dec 13 | 29,106 | 4,943 | 6,643 | 6,488 |
Quality Earnings: 4548 has high quality earnings.
Growing Profit Margin: 4548's current net profit margins (5.3%) are higher than last year (3.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4548 has become profitable over the past 5 years, growing earnings by 45.2% per year.
Accelerating Growth: 4548's earnings growth over the past year (68.3%) exceeds its 5-year average (45.2% per year).
Earnings vs Industry: 4548 earnings growth over the past year (68.3%) exceeded the Pharmaceuticals industry 12.2%.
Return on Equity
High ROE: 4548's Return on Equity (2.7%) is considered low.